epratuzumab   Click here for help

GtoPdb Ligand ID: 8088

Synonyms: 90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name)
Immunopharmacology Ligand
Compound class: Antibody
Comment: Epratuzumab is a humanized monoclonal antibody. It is derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). Epratuzumab has antineoplastic and antiinflammatory actions [1].
The antibody can be conjugated with tetraxetan (DOTA) which allows chelation of radionucleotides such as yttrium-90 [5].
No information available.
Summary of Clinical Use Click here for help
Epratuzumab is an investigational immunotherapy in Phase 3 clinical trial for the treatment of systemic lupus erythematosus (SLE; failure to show efficacy reported in [3]) [8], relapsed acute lymphoblastic leukemia (ALL) and relapsed/refractory, aggressive non-Hodgkin's lymphoma (NHL). Click here to link to ClinicalTrials.gov's full listing of registered epratuzumab trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Epratuzumab binds to the CD22 glycoprotein on the surface of mature and malignant B-cells and appears to stimulate antibody-dependent cellular cytotoxicity (ADCC) as its main anti-tumour mechanism [2,4].